Suraksha Diagnostic Ltd. · NSE:SURAKSHA
Suraksha Diagnostic — Q1 FY27 Earnings Presentation
55 slides from Suraksha Diagnostic's earnings presentation, Aug 12, 2026
Slide 1: Cover letter to stock exchanges for earnings call presentation
Date: 12 August 2026 To The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA D
Slide 2: Suraksha Diagnostic Limited Investor Presentation Q1 FY27
SURAKSHA DIAGNOSTIC LIMITED Investor Presentation | Q1 FY27
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any s
Slide 4: Q1 FY27 Result Highlights
Suraksha Clinic & Diagnostics Q1 FY27 RESULT HIGHLIGHTS
Slide 5: Q1 FY27 Performance
Q1 FY27 Performance Financial Performance YoY Growth % Revenue from Operations 21% 28% 40% INR 876.5 Mn Revenue Growth % EBITDA Growth % PAT Growth % Key Metrics EBITDA | EBITDA Margin % INR 315.3 Mn | 36.0% Revenue per Patient EBITDA per Patient B2C Revenue % INR 2,321 INR 835 91% PAT | PAT Margin
Slide 6: Management Commentary on Q1 FY27 Results
Management Commentary on Q1 FY27 Results “Suraksha has begun FY27 on a strong footing. We have delivered YoY growth of 21% with an EBIDTA margin of 36.0% and PAT of 14.7% in Q1 FY27. Network expansion continued through the quarter with one hub and three spoke centres commissioned during Q1 FY27, We
Slide 7: Q1 FY27 Key Financial Performance
Q1 FY27 Key Financial Performance Total Income (INR Mn) EBITDA (INR Mn) PAT (INR Mn) +21% +28% +40% 887 315 128 822 735 247 252 92 62 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Suraksha Diagnostic Limited| Investor Presentation 6
Slide 8: Q1 FY27 Key Operating Metrics
Q1 FY27 Key Operating Metrics Number of Centres Number of patients (Mn) Number of Tests (Mn) 72 0.38 2.10 68 1.92 1.97 0.34 58 0.30 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Revenue / Patient (INR) EBITDA / Patient (INR) 2,321 835 2,264 2,101 707 719 Q1 FY26 Q4 FY26 Q1
Slide 9: Statement of Profit & Loss (Consolidated)
Statement of Profit & Loss (Consolidated) Particulars (INR Mn) Q1 FY27 Q1 FY26 Y-o-Y Q4 FY26 Q-o-Q FY26 Revenue from Operations 876.45 725.86 814.12 3,104.14 Other Income 10.88 9.06 7.85 31.64 Total Revenue 887.33 734.92 20.7% 821.97 7.9% 3135.78 Cost of Material Consumed 99.95 87.51 101.58 364.75 E
Slide 10: IGAAP vs IND AS
IGAAP vs IND AS Q1 FY27 Ind AS PARTICULARS (INR Mn) Ind AS IGAAP Impact TOTAL INCOME 887.3 0.97 886.4 EBITDA 315.3 67.1 248.2 EBITDA MARGIN 36.0% 28.3% INTEREST + DEPRECIATION 150.0 83.7 66.4 PAT 128.4 - 145.0 PAT MARGIN 14.7% 16.5% Note: The key difference between Indian GAAP (IGAAP under AS 19) an
Slide 11: EBITDA Margin (%) Breakdown by Center Age
EBITDA Margin (%) Breakdown by Center Age Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 EBITDA EBITDA EBITDA EBITDA EBITDA Margin (%) Margin (%) Margin (%) Margin (%) Margin (%) 34.0% 31.7% 30.6% 30.9% 36.0% 42 centres 45 centres > 2 yrs1 > 2 yrs2 38.2% 36.9% 36.2% 36.5% 40.9% 16.32 26 centres 27 centres
Slide 12: Key Developments and Expansion
KEY DEVELOPMENTS AND EXPANSION
Slide 13: Revenue by Geography
Revenue by Geography 3% 1% Greater Kolkata Bihar Assam 67% Rest of Bengal 29% 29% Assam 67% 3% Tripura Bihar West Bengal 1% Jharkhand Upcoming Center Launched Center Suraksha Diagnostic Limited| Investor Presentation 12
Slide 14: Expansion Plans – Centres FY27
Expansion Plans – Centres FY27 Launched till date Geography in FY27 Upcoming Greater Kolkata 1 Hub · 1 Spoke 1 Spoke Bihar Assam Rest of Bengal 1 Hub · 4 Spokes 1 Hub · 5 Spokes Jharkhand 1 Hub 1 Hub Tripura Tripura - 1 Hub Greater Kolkata Rest of Bengal Assam 1 Spoke 1 Spoke Jharkhand Bihar - 1 Hub
Slide 15: Launched State-of-the-Art Hub centre at Mukundapur in June 2026
Launched State-of-the-Art Hub centre at Mukundapur in June 2026 Equipped with a 3T MRI, bringing advanced imaging capability to the Mukundapur catchment Suraksha Diagnostic Limited| Investor Presentation 14
Slide 16: Launched State-of-the-Art Hub centre at Mukundapur in June 2026
Launched State-of-the-Art Hub centre at Mukundapur in June 2026 Equipped with a 3T MRI, bringing advanced imaging capability to the Mukundapur catchment 3T MRI suite CT suite Suraksha Diagnostic Limited| Investor Presentation 15
Slide 17: Inaugurated our New AIIR centre in June 2026
Inaugurated our New AIIR centre in June 2026 Suraksha Diagnostic Limited| Investor Presentation 16
Slide 18: Inaugurated our New AIIR centre in June 2026
Inaugurated our New AIIR centre in June 2026 With Day-care Facility Suraksha Diagnostic Limited| Investor Presentation 17
Slide 19: Commissioned Two New Spoke Centres in June 2026
Commissioned Two New Spoke Centres in June 2026 Spoke centres at Malegaon and Arambagh, adding catchment density around our established hubs Malegaon Arambagh Spoke centre Spoke centre Suraksha Diagnostic Limited| Investor Presentation 18
Slide 20: Launched State-of-the-Art Hub Centre at Berhampur in August 2026
Launched State-of-the-Art Hub Centre at Berhampur in August 2026 Anchored by an in-house laboratory and 3T MRI Centre exterior Reception Suraksha Diagnostic Limited| Investor Presentation 19
Slide 21: Launched State-of-the-Art Hub Centre at Berhampur in August 2026
Launched State-of-the-Art Hub Centre at Berhampur in August 2026 3T MRI suite In-house laboratory Suraksha Diagnostic Limited| Investor Presentation 20
Slide 22: Entered Jharkhand with a New Hub Centre at Dhanbad in August 2026
Entered Jharkhand with a New Hub Centre at Dhanbad in August 2026 Our first centre in Jharkhand, equipped with an MRI and offering integrated pathology and radiology Centre exterior MRI suite Suraksha Diagnostic Limited| Investor Presentation 21
Slide 23: Launched our New Centre at Karimpur in July 2026
Launched our New Centre at Karimpur in July 2026 Offering pathology and radiology services, extending our reach across Nadia district Building front X-ray room Suraksha Diagnostic Limited| Investor Presentation 22
Slide 24: Commissioned a New Spoke Centre at Nabadwip in August 2026
Commissioned a New Spoke Centre at Nabadwip in August 2026 Centre exterior Reception Suraksha Diagnostic Limited| Investor Presentation 23
Slide 25: Genomics Scaling Rapidly
Genomics Scaling Rapidly Building a Genomics Franchise Growth in Genomics Revenue (In Mn) • Launched July 2025 — Suraksha Genomics, our dedicated vertical for 13.7 advanced genetic and molecular diagnostics, built on NABL/CAP- accredited workflows 11.5 • Full-spectrum capability — prenatal diagnosti
Slide 26: Company Overview
Suraksha Clinic & Diagnostics COMPANY OVERVIEW
Slide 27: Vision, Mission and Values
Vision, Mission and Values Medium-term Long-term We aspire to metamorphise the Company into the most reputable and Our vision is to be the most trusted and innovative diagnostic centre and cutting-edge diagnostic facility, providing precise, prompt, affordable set the standard for diagnostics in the
Slide 28: Evolution to the Largest Integrated Diagnostic Chain in East India
Evolution to the Largest Integrated Diagnostic Chain in East India Received second round of funding from OrbiMed Exit of Lighthouse Funds IPO and listing on Built fully BSE and NSE comprehensive diagnostic centre, 4 Labs 9 Labs under brand ‘Suraksha’ 1 centre 5 centres 25 centres 53 centres 68 centr
Slide 29: Deeply Entrenched in the Vital Geography of West Bengal
Deeply Entrenched in the Vital Geography of West Bengal 69 Centers in West Bengal 2 1 No. of centres >10 centres 1 4 to 10 centres 3 centres 2 centres Bihar Assam 1 centre • 4th most populous state in India • Fragmented market with low penetration of Population Legend Meghalaya chained diagnostic ce
Slide 30: Hub & Spoke Operating Model
Hub & Spoke Operating Model Modalities Offered Key Stats # of doctors & Area Hub Centres employees / centre Large Gastroenterology Dexa OPG Mammo Centres 30-40 5,000 – 8,000 sq. ft CT Scan Neurology USG X-Ray Cardiology Pathology Medium 20-25 2,500 – 5,000 sq. ft Centres CT-Scan Neurology USG X-Ray
Slide 31: …..With Demonstrated Success
…..With Demonstrated Success Demonstrated success in Kolkata region with significant potential Operational Network(1) for future growth2 1 Central Lab (equipped to conduct all pathology 7 Satellite Labs 17 Hub Centres sample collection, basic and advanced radiology tests) (co-located with hub centre
Slide 32: Well Equipped Clinical Infrastructure (1/2)
Well Equipped Clinical Infrastructure (1/2) Suraksha Diagnostic Limited| Investor Presentation 31
Slide 33: Well Equipped Clinical Infrastructure (2/2)
Well Equipped Clinical Infrastructure (2/2) Suraksha Diagnostic Limited| Investor Presentation 32
Slide 34: Customer Convenience Through Value Added Services
Customer Convenience Through Value Added Services Value Added Services enhancing customer experience and convenience Home Collection Allows samples to be collected from the consumers’ locations, such as their homes or offices SMS Alerts Customers receive an SMS to Customer download the report throug
Slide 35: Well-established Operational Network - Greater Economies of Scale
Well-established Operational Network - Greater Economies of Scale Report Flow Patient P.A.C.S RAD IMAGE (Software) (Scrutiny) (Report) Image/Report Flow Image Flow Patients Flow #17 #1 Hub Centre Flagship Reference Lab Doctor #7 #49 Spoke Centre SATELLITE LAB Polyclinic Doctor Customers Samples Coll
Slide 36: Positioned to Leverage IT Infrastructure
Positioned to Leverage IT Infrastructure Suraksha’s Integrated System for Diagnostics LIMS Integration RIS and PACS Advanced ERP-enabled Error Reduction and Workflow Imaging Tools Operations Turnaround Time Our Laboratory The Radiology PACS includes DICOM Our ERP system handles Automation reduces In
Slide 37: Experienced Board Of Directors
Experienced Board Of Directors Dr. Somnath Chatterjee Ritu Mittal Mr. Satish Kumar Verma Chairman & Joint Managing Director Joint Managing Director & Chief Non-Executive, Non-Independent Director Executive Officer ▪ Associated with Suraksha since ▪ 41+ years of experience in management ▪ Associated
Slide 38: Dynamic And Diverse Management Team to Deliver Next Phase of Growth
Dynamic And Diverse Management Team to Deliver Next Phase of Growth Niren Kaul Balgopal Jhunjhunwala Sangeeta Chakraborty Chief Sales Officer Regional Business Head General Manager, Operations ▪ 23+ years of experience, including with Bharti Hexacom ▪ 16+ years of experience ▪ 27+ years of experienc
Slide 39: Marquee Shareholders Invested in our Story
Marquee Shareholders Invested in our Story Shareholding Pattern as at 30th June 2026 13.47% 49.10% 23.23% 14.21% FIIs DIIs Others Promoter & Promoter Group Source: BSE DIIs include Mutual Funds, AIFs and Central / State governments FIIs include Foreign Direct Investments and Foreign Portfolio Invest
Slide 40: Key Awards & Recognition
Key Awards & Recognition 2017 2019 2021 Best quality in service delivery(1) Best customer service in healthcare(1) Business leader of the year(2) 2021 2022 2023 Certificate of excellence Outstanding diagnostic chain of Awards & certificate of excellence(3) in exemplary trust & commitment eastern Ind
Slide 41: Strategy & Outlook
Clinic & Diagnostics STRATEGY & OUTLOOK
Slide 42: Leveraging Strengths to Drive Competitive Advantage
Leveraging Strengths to Drive Competitive Advantage Largest diagnostic chain with a Technologically advanced Track record of profitability dominant position in Eastern clinical infrastructure and and consistent financial India; well-positioned to benefit trained personnel ensuring performance from t
Slide 43: Strategic Levers to Drive Future Growth
Strategic Levers to Drive Future Growth Expand footprint in Eastern and Enhance one-stop diagnostic North-Eastern India through model by augmenting medical organic as well as inorganic consultation services’ share route Strengthen B2B and Invest in technology to institutional partnerships to enhance
Slide 44: Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets Expand in adjacent geographies of Eastern and Consolidate leading position in the core geography Supplement organic growth with selective acquisitions North-Eastern India Open additional diagnostic centres and increase Identi
Slide 45: Key Differentiating Factors
Key Differentiating Factors Polyclinic Diversified in terms of revenue from services % of FY26 Revenue 50% 44% 6% Pathology Radiology Other 160+ 1,000+ Chambers1 Doctors1 Omnichannel medical consultation services via online and offline modes through Other includes Revenue from Doctor Consultancy and
Slide 46: Industry Overview
Clinic & Diagnostics INDUSTRY OVERVIEW
Slide 47: Industry: Poised For High Growth; Shifting Towards Organized Market
Industry: Poised For High Growth; Shifting Towards Organized Market Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28 Organized players gaining market share from standalone labs at a steady rate CAGR 10-12% 1,275-1,375 36-40% 36-40% 860-870 13- 20- 17% 24% 45-49% 35-39% FY24E FY2
Slide 48: Eastern India - An Underserved Market With Premium Pricing
Eastern India - An “Underserved” Market With Premium Pricing Disparity in access to accredited testing services in Region has the lowest number of NABH East India(1) market also offers premium Eastern(1) India relative to population needs accredited hospitals pricing for diagnostic tests 430 80-90 8
Slide 49: Historical Financials and Operating Metrics
HISTORICAL FINANCIALS AND OPERATING METRICS
Slide 50: Consolidated Historical Financial Performance
Consolidated Historical Financial Performance Total Income (INR Mn) EBITDA (INR Mn) PAT (INR Mn) 25.0% 33.7% 33.8% 31.8% 3.2% 10.6% 12.3% 10.1% +62% +107% +415% 3,136 986 314 310 851 2,559 736 2,223 231 1,937 475 61 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Suraksha Diagnostic Limi
Slide 51: Consistent Performance Over the Years
Consistent Performance Over the Years Number of Centres Number of Patients (Mn) Number of Tests (Mn) 68 1.37 8.15 55 1.11 1.14 1.19 6.69 48 5.98 43 5.17 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Revenue / Patient (INR) EBITDA / Patient (INR) ROE % ROCE % +32% +68% 2264 2118 715 719
Slide 52: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (₹ million) FY26 FY25 FY24 FY23 FY26 vs FY25 FY23-26 CAGR (%) Revenue from Operations 3,104.14 2520.93 2187.09 1901.34 Other Income 31.6 38.46 35.51 35.53 Total Revenue 3135.78 2559.39 2222.59 1936.87 22.5% 17.4% Cost of Material Consumed 364.75 295.1
Slide 53: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (₹ million) FY26 FY25 FY24 FY23 Particulars (₹ million) FY26 FY25 FY24 FY23 Assets Equity Non-current assets Equity share capital 104.16 104.16 85.29 85.29 Other equity 2,344.32 2,008.24 1,725.1 1,490.26 Property, plant and equipment 1,935.78 1,471.37 1,350.50
Slide 54: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (₹ million) FY26 FY25 FY24 FY23 Profit before Tax 445.57 414.05 314.53 67.48 Adjustment for Non-Operating Items 526.22 428.61 413.29 397.12 Operating Profit before Working Capital Changes 971.79 842.67 727.82 464.6 Changes in Working Capital -19.92 -103.2
Slide 55: Thank You
Company : Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 investors@surakshanet.com Email: investors@surakshanet.com Investor Relations Advisors : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services Mr. Sumeet Khaitan sumeet.khaitan